Previous close | 112.12 |
Open | 112.68 |
Bid | 107.14 x 1200 |
Ask | 118.75 x 800 |
Day's range | 112.08 - 113.77 |
52-week range | 82.82 - 122.16 |
Volume | |
Avg. volume | 1,476,990 |
Market cap | 255.777B |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | 37.21 |
EPS (TTM) | 3.03 |
Earnings date | N/A |
Forward dividend & yield | 1.57 (1.49%) |
Ex-dividend date | 25 Mar 2022 |
1y target est | 129.66 |
Investors are optimistic about CVS Health's (CVS) robust revenue growth across its operating segments.
The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.
The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.